Unimed to market Searle Maxaquin antibiotic effective March 1.
SEARLE MAXAQUIN RIGHTS GRANTED TO UNIMED under a marketing and distribution agreement between the two companies that will be effective March 1. Unimed will acquire U.S. marketing and distribution rights to the fluoroquinolone anti-infective in exchange for sales-based distribution fee payments. Searle, which had marketed Maxaquin (lomefloxacin) since its 1992 approval, will continue to manufacture the drug for Unimed.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth